Medical Oncology

Neoadjuvant chemotherapy in muscle invasive bladder cancer

  • Evren Süer
  • Kadir Türkölmez

Bull Urooncol 2012;11(1):74-78

Aim of the Review:

The 5 year estimated survival outcomes for muscle invasive bladder cancer was demonstrated at the interval of 60-70% in best series The aim of this review is to demonstrate the efficacy of neoadjuvant chemotherapy in muscle invasive bladder cancer.

New Findings:

The meta-analyses demonstrated a mean 5% contribution of cisplatin based chemotherapy regimes for the survival of these patients. Successful local treatment is crucial for this well tolerated therapy.


Neoadjuvant chemotherapy enhances survival with reasonable toxicity and mortality rates.

Keywords: bladder cancer , neoadjuvant chemotherapy, radical cystectomy, survival